Ultra-Low Power 'Whisper' Architecture Raises the Bar for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ultra-Low Power 'Whisper' Architecture Raises the Bar for Connectivity IP in IoT, Wearables and More

LONDON, July 24, 2014 (GLOBE NEWSWIRE) -- Imagination Technologies (IMG.L) announces the new Ensigma Series4 'Whisper' low-power radio processing unit (RPU) architecture, designed to drive a new generation of wearables, IoT and other connected devices where ultra-low power consumption and low cost points are key.

Tomorrow's IoT, wearables and other connected embedded devices demand more than the evolution of existing connectivity chipsets; they require solutions designed specifically for these emerging product categories, with an eye on power consumption, cost and flexibility.

Says Tony King-Smith, EVP marketing, Imagination: "Many devices claiming to address IoT today are in fact repurposed from other markets such as mobile or embedded, but don't fully address the extreme low power and cost requirements that this market will demand. With our existing Ensigma RPUs, customers are already building a range of life-style devices. With new Ensigma 'Whisper' RPUs, customers can create a whole new generation of life-enhancing and efficiency-focused devices targeting markets as diverse as eHealth, energy, agriculture, security and many other areas. Imagination is delivering the ultra-low power CPUs, GPUs and RPUs that provide a foundation for building these devices, supported by optimized hardware IP platforms and our FlowCloud technology for true device-to-cloud connectivity."

Low-power Ensigma 'Whisper' RPUs, like their high-performance Ensigma Explorer RPU counterparts, provide multi-standard support in a single architecture, designed to enable customers to bring standards such as Wi-Fi, Bluetooth Classic, Bluetooth Smart, NFC, GNSS and other existing or emerging low-power connectivity technologies onto their SoCs. By bringing this functionality on-chip, customers can minimize power consumption, silicon footprint and system cost compared with conventional solutions.

Why 'Whisper'?

'Whisper' RPUs are designed specifically for next-generation ultra-low power, cost-sensitive devices.

  • Configurable: the 'Whisper' architecture supports a broad range of lower bitrate connectivity standards needed in IoT and other small-footprint connected devices
  • Power-efficient: 'Whisper' RPUs feature highly optimized, configurable hardware with Imagination's PowerGearing for Ensigma that optimizes both static and dynamic power consumption in the cores
  • Clean: the tightly coupled modem/processor in 'Whisper' can eliminate the host processor or alleviate its load, for the smallest embedded system size and lowest power consumption

The Ensigma family of RPUs, including 'Whisper' and Explorer, is designed to meet the needs of a range of devices and applications.

  • Scalable: 'Whisper' and Explorer RPUs address applications from ultra-low power to maximum performance, and with a common API, customers can reuse software across the platforms
  • Proven: Ensigma RPUs are shipping today in numerous low-power audio and connectivity devices with a growing range of designs also in the pipeline
  • Complete: to reduce customers' time to market, Ensigma RPUs are uniquely provided as end-to-end offerings including RF if needed, and certifications

Connected Processor IP Platform

For IoT and other next-generation connected applications, customers can benefit from the combination of Ensigma RPUs and MIPS CPUs – the industry's smallest and highest performance embedded 32-bit CPUs. Together, these flexible, scalable cores are designed to revolutionize IoT applications by delivering the only truly embedded Connected Processor IP Platform. With hardware virtualization and multi-context security across the MIPS Warrior range of CPUs, these cores are designed to deliver to the emerging requirements of modern systems and add even more benefits. Customers can also leverage Imagination's FlowCloud device-to-cloud platform to create complete IoT/cloud solutions.

Says King-Smith: "With Imagination's Connected Processor IP Platform, customers can leverage an industry standard CPU with a broad array of software and tightly integrated communications. We believe this is a unique and powerful offering for the industry."

Availability

Imagination will start to roll out a line of Ensigma 'Whisper' cores in Q4 2014. Contact info@imgtec.com for more information.

About Imagination Technologies

Imagination is a global technology leader whose products touch the lives of billions of people across the globe. The company's broad range of silicon IP (intellectual property) includes the key processing blocks needed to create the SoCs (Systems on Chips) that power all mobile, consumer and embedded electronics. Its unique software IP, infrastructure technologies and system solutions enable its customers get to market quickly with complete and highly differentiated SoC platforms. Imagination's licensees include many of the world's leading semiconductor manufacturers, network operators and OEMs/ODMs who are creating some of the world's most iconic products. See: www.imgtec.com.

Follow Imagination on Twitter, YouTube, LinkedIn, RSS, Facebook and Blog.

Imagination Technologies and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries. All other logos, products, trademarks and registered trademarks are the property of their respective owners.

Imagination Technologies' Press Contacts: UK: David Harold +44 (0)1923 260 511 USA: Jen Bernier-Santarini +1 408-530-5178

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading